Eupraxia Pharmaceuticals Inc (EPRX.TO) has seen a modest increase in its stock price over the past week, reflecting recent market activity and company developments.
Eupraxia Pharmaceuticals Inc, a player in the health care sector, closed at C$9.09 on Wednesday, with a slight daily decline of 0.21%. However, the stock has appreciated by 2.52% over the past week. While no major news has emerged recently, the company's public offerings have caught the attention of investors.
Advertisement
Eupraxia Pharmaceuticals Inc
EPRX.TO
EPRX.TO
Eupraxia Pharmaceuticals Inc
WealthAwesomeAdvertisement
Market cap
$612.11M
52W high
$12.86
52W low
$6.94
1W change
+2.52%
Beta
1.50
Analyst Price Targets
Based on analyst covering EPRX
Wall Street analysts forecast EPRX stock price to rise 71.1% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$16.00
+71.1% Upside
Current Price
C$9.35
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EPRX's historical volatility
30-Day Vol
56.0%
Annualized
90-Day Vol
55.7%
Annualized
Trend (90d)
-25.3%
Annualized drift
90d Mean
C$8.54
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$9.07 | C$7.48 – C$11.01 |
| 60 trading days | C$8.80 | C$6.70 – C$11.57 |
| 90 trading days | C$8.54 | C$6.11 – C$11.94 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Eupraxia's recent public offerings and ongoing clinical trials may influence investor sentiment, despite the stock's overall decline this year. Investors should keep an eye on the company’s financial health and clinical progress as indicators of future performance.
C$9.09 closing price with a 1D change of -0.21%.
The stock has a 52-week range of C$6.94 to C$12.86, indicating potential volatility and room for growth.
Bull case
Eupraxia's recent public offerings have strengthened its financial position, providing capital for ongoing clinical trials. The company is showing promising results in its lead program, EP-104GI, which could give it a competitive edge in the market.
Bear case
Despite recent gains, Eupraxia's stock is still down 10.61% year-to-date, and the company continues to report negative earnings. The stock's high volatility, indicated by a beta of 1.50, may pose risks for investors.
Recent Price Action
Advertisement
Eupraxia Pharmaceuticals Inc (EPRX.TO) experienced a closing price of C$9.09 on Wednesday, marking a slight decline of 0.21% for the day. Over the past week, the stock has gained 2.52%, indicating a positive trend amidst a challenging year, with a year-to-date decrease of 10.61%. The stock's recent movements reflect investor sentiment and market conditions.
Company News and Catalysts
While no major news has been reported in the past week, Eupraxia has recently announced the pricing and completion of public offerings, raising significant capital. On February 19, 2026, the company priced a public offering aiming to raise US$55 million, followed by the successful closure of a US$63.2 million offering on February 20, 2026. These developments may provide the necessary funds for ongoing clinical trials and operational expenses, which investors are closely watching.
Technical Picture
The technical outlook for Eupraxia Pharmaceuticals shows a last close of C$9.09, slightly above its 50-day moving average of C$9.03, which is up 0.6%. However, it remains below the 200-day moving average of C$9.76, indicating a longer-term downtrend. The stock is currently trading within a 52-week range of C$6.94 to C$12.86, suggesting significant potential for volatility. The recent trading volume of 69,212 shares is below the 20-day average of 57,778 shares, indicating lower trading activity.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
